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Abstract
Background: Congenital muscular dystrophy type 1A is caused by mutations in the LAMA2 gene that encodes the
laminin a2 chain, a component of the skeletal muscle extracellular matrix protein laminin-211. The clinical
spectrum of the disease is more heterogeneous than previously thought, particularly in terms of motor
achievement and disease progression. We investigated clinical findings and performed molecular genetic analysis
in 3 families from Saudi Arabia and 1 from Sudan in whom congenital muscular dystrophy 1A was suspected
based on homozygosity mapping and laminin a2 chain deficiency.
Methods: We investigated 9 affected individuals from 1 Sudanese and 3 Saudi families in whom MDC1A was
suggested by clinical, neuroimaging and/or pathological findings and by homozygosity mapping at the LAMA2
locus. Morphological and immunohistochemical analysis were performed in 3 patients from the 3 Saudi families.
SSCP analysis, DNA sequencing and microsatellite analysis were carried out in the 4 index cases.
Results: A previously described mutation in the LAMA2 gene, a homozygous T > C substitution at position +2 of
the consensus donor splice site of exon 26, was found in the 4 index patients. Clinical evaluation of 9 patients
from the 4 families revealed variable disease severity particularly as regards motor achievement and disease
progression. Microsatellite analysis showed an identical mutation-associated haplotype in the 4 index cases
indicating a founder effect of the mutation in all 4 families.
Conclusions: Our data provide further evidence that the clinical spectrum of MDC1A due to a single mutation is
heterogeneous, particularly in terms of motor achievement and disease progression, making it difficult to give a
reliable prognosis even in patients with identical LAMA2-associated haplotype. The c.3924 + 2 T > C mutation to
date has been found only in patients originating from the Middle East or Sudan; therefore laminin 2 chain
deficiency in patients from those regions should initially prompt a search for this mutation.
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Background
Congenital muscular dystrophy type 1A (MDC1A) is an
autosomal recessive neuromuscular disorder caused by
mutations in the LAMA2 gene encoding the laminin a2
chain [1] a component of the skeletal muscle extracellular
matrix protein laminin-211 [2]. Laminin-211, the most
abundant laminin in muscle, is also expressed in Schwann
cells, synaptic basal lamina of peripheral nerves, heart, epi-
dermis and fetal trophoblastic tissue [3]. MDC1A is char-
acterized by generalized hypotonia and severe muscle
weakness at birth with delayed motor development, proxi-
mal joint contractures, inability to achieve independent
walking, high CK levels and a clinically asymptomatic
abnormality of the central white matter on brain magnetic
resonance imaging (MRI) [4-6]. Several studies have also
documented respiratory insufficiency, often leading to
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any medium, provided the original work is properly cited.death in early childhood, and feeding difficulties. Clinical
and subclinical cardiomyopathy, sensory and motor
demyelinating neuropathy, and (late) external ophthalmo-
plegia, also occur [7]. Numerous mutations have now
been identified in the LAMA2 gene, resulting in either
complete or partial protein deficiency. However, the clini-
cal spectrum is more heterogeneous than previously
thought: a severe phenotype associated with partial expres-
sion of a laminin a2 chain isoform has been reported [8]
as well as clinically mild forms with total lack of laminin
a2 chain [9-11].
In the present study we report on three consangui-
neous Saudi Arabian families and a Sudanese family with
the previously described [12] homozygous mutation
c.3924 + 2 T > C in the LAMA2 gene. This mutation
leads to aberrant splicing of exon 26 and results in an in-
frame deletion of 63 amino acid residues from domain
IVa of the laminin a2 chain. We also performed haplo-
type analysis to investigate a hypothesized founder effect
of this mutation, and examined the relationship between
the mutation and clinical phenotype in the 4 families.
Methods
Subjects
Inclusion criteria for this study were a) clinical, neuroi-
maging and/or pathological findings suggestive of
MDC1A; and b) homozygosity at the LAMA2 locus if
consanguinity was confirmed or suspected. We investi-
gated 9 affected individuals from 4 families. Patients 1
and 2, a male and a female, were Sudanese; they were
born to parents from the same small village and had 7
healthy siblings. Patient 3 and 4 were males born to 3
rd cousin Saudi parents; family history revealed 2
deceased affected siblings with the same diagnosis and 5
healthy siblings. Patients 5 and 6 were both males born
to a 1st cousin Saudi union and had 5 unaffected broth-
ers. Patients 7, 8 and 9 were one male and two females
also born to a 1st cousin Saudi union with another 2
unaffected male and female offspring. All patients were
examined by a pediatric neurologist at a tertiary referral
clinic and clinical features are summarized in Additional
f i l e1 :T a b l eS 1 .Am u s c l eb i o p s yw a sp e r f o r m e da f t e r
informed consent in patients 3, 5, 6 and 8.
Written, informed consent was obtained from the sub-
jects or their parents/legal guardians. Research was con-
ducted according to protocols approved by the
Institutional Review Boards of Children’sH o s p i t a lB o s -
ton, University of Iowa, King Saud University and Besta
Neurological Institute, and in compliance with the Hel-
sinki Declaration and local legislation.
Immunohistochemistry
Immunohistochemical analyses were performed on mus-
cle biopsies from patients 3, 6 and 8, from the 3 Saudi
families. Patient 3’s muscle was analyzed using the fol-
lowing anti-human laminin a2-chain monoclonal anti-
bodies: 5H2, recognizing the G-domain (Gibco/BRL,
Gaithersburg, USA), 300 kDa NCL-merosin (Novocastra,
New Castle-upon-Tyne, UK), and 4H8-2 (gift to KPC
from L. Sorokin) recognizing the N-terminus of the pro-
tein. Patient 8’s muscle was tested only with the 300
kDa monoclonal.
In addition, the expression of dystrophin [6A9 at 1:50,
Developmental Studies Hybridoma Bank (DSHB), The
University of Iowa], a-dystroglycan (VIA4-1 at 1:50,
Millipore), a-dystroglycan (7D11 at 1:100, DSHB), perle-
can (a716 at 1:1000, Millipore) and collagen VI (5 C6 at
1:20, DSHB) were investigated in patient 3. Dystrophin,
a-, b-a n dg-sarcoglycan (all from Novocastra) were
tested in patients 6 and 8.
Cryosections were incubated in primary antibodies
d i l u t e di nP B Sf o r1 - 2ha tr o o mt e m p e r a t u r eo ro v e r -
night at 4°C. Slides were washed 5 min ×2 in PBS, then
secondary antibodies were applied in PBS for 30 min-1
h at room temperature. After washing again 5 min ×2 in
PBS, coverslips were mounted using ProLongGold with
DAPI (Molecular Probes Inc, Eugene, OR, USA). Sec-
ondary antibodies were either goat-anti-mouse tagged
with AlexaFluor488 or goat-anti-rat tagged with Alexa-
Fluor594 (both from Molecular Probes).
Molecular analyses
Genomic DNA was extracted from peripheral blood and
analyzed by the polymerase chain reaction touchdown
method using oligonucleotide primers flanking the
intron-exon junctions of all 65 LAMA2 exons (exon
numbering according to the Leiden muscular dystrophy
database) [10]. Aberrant conformers, identified by sin-
gle-strand conformation polymorphism (SSCP) analysis,
were sequenced using an ABI Prism 3100 analyzer
(Applied Biosystems, Foster City, CA, USA).
Total RNA was prepared from skeletal muscle using
TRI Reagent (Ambion, Inc. Austin, TX). The isolated
RNA was reverse transcribed using a First-Strand cDNA
Synthesis Kit (Roche Molecular Biochemicals, Basel,
Switzerland), the resulting cDNA was amplified by
reverse transcriptase PCR (RT-PCR) and sequenced
using appropriate primers.
Haplotyping
Haplotype analysis was performed on genomic DNA using
microsatellite markers provided by Genethon human
genetic linkage map [13] and flanking the LAMA2 gene:
upstream (D6S407) and downstream (D6S1620, and
D6S1705); and six intragenic polymorphisms: G1905A,
A2848G, G5515A, A5551G, C5579A and G6286A [14].
Allele frequency of polymorphisms in a reference popula-
tion are reported in Guicheney et al. [14].
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Clinical findings are summarized in Additional file 1:
Table S1. All patients were floppy babies and manifested
with generalized hypotonia. Severe proximal weakness
was also present from birth or developed within the first
6 months. In all cases motor milestones were delayed.
Five of the 9 patients achieved independent walking at
3, 3.5 and 4 years, which was retained at least until 8,
11, 12 or 13 years respectively, when last seen. Patients
3-6, who never walked, could sit or stand with or with-
out support. CK was normal in patient 9, and slightly to
markedly increased in all others.
Electrocardiogram (performed in 5 patients) and echo-
cardiogram (performed in 4 patients) were normal; car-
diac signs were reported in none of the patients.
Respiratory support was necessary in patient 3 who died
of respiratory failure at 7 years and in patient 5 who
also died of respiratory failure at 16 years. No mental
retardation, epilepsy or eye abnormalities were observed.
MRI or CT, performed in 8 patients, revealed white
matter changes in all cases (Figure 1). Patients 3 and 6
underwent EMG, and myopathic features were found in
both cases.
A muscle biopsy from patient 3 (taken at 5 weeks)
showed mild dystrophic features; whereas muscle biop-
sies from patients 5 (taken at 3 years and 2 months), 6
(taken at 5 years) and 8 (taken at 4 years) showed
marked dystrophic features. Immunofluorescence analy-
sis of the laminin a2 chain was only performed in
patient 3 (with 3 antibodies) and in patient 8 (1 anti-
body); this revealed greatly reduced staining intensity
with the 3 antibodies in patient 3 (Figure 2) and with
the single antibody in patient 8 (data not shown). Dys-
trophin and dystrophin-associated proteins were normal
in patients 3, 6 and 8.
SSCP analysis in patients 1, 4, 5 and 7 (index cases)
revealed abnormal conformers in exon 26. The exon
was sequenced and showed a T > C substitution at posi-
tion +2 of the consensus donor splice site. This muta-
tion has been described previously in two siblings from
a consanguineous Saudi family unrelated to ours [12].
Direct sequencing of the cDNA revealed a 189 bp in-
frame deletion, corresponding to aberrant skipping of
the whole of exon 26, with loss of 63 amino acids (resi-
dues 1246-1308) from domain IVa of the protein (See
Additional file 2: Figure S1).
Because of the consanguinity in the Saudi families and
presumed consanguinity in the Sudanese family, it is
likely that all affected siblings are homozygous for this
mutation.
Investigation of flanking and intragenic microsatellite
markers of the LAMA2 gene in the 4 index cases indi-
cated an identical mutation-associated haplotype (con-
taining the mutation) between marker D6S407 and
Figure 1 T2-weighted MRI images of patient 7, taken at the
age of 19 months. Showing abnormal periventricular and sub-
cortical white matter signal.
Figure 2 H&E in control (A) and MDC1A (B) muscle (bar = 25
μm); and immunohistochemistry (C-H) in control (C,E,G) and
patient 3 muscle (D,F,H) laminin a2 chain with 5H2 (C,D), 300
kDa (E,F) and 4H8 (G,H) antibodies. Nuclei are stained with DAPI,
pseudo-colored in red (bar = 50 μm).
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suggesting remote consanguinity and a founder effect in
all 4 families. By contrast, the downstream markers
(D6S1620, and D6S1705) were not identical in the 4
cases.
Discussion
In 3 families from Saudi Arabia and 1 from Sudan we
have identified a previously reported homozygous c.3924
+ 2 T > C mutation in the LAMA2 gene associated with
variable clinical phenotype. The main phenotypic differ-
ences among our 9 cases regard motor achievement.
Patients 1 and 2 from the Sudanese family walked at 4
years; patients 7, 8 and 9 from a Saudi family walked at
3, 3.5 and 4 years, respectively. These 5 patients were
still walking at 8, 11, 12 and 13 years when last seen,
while patients 3, 4, 5, and 6 from the 2 other Saudi Ara-
bian families never walked.
CK levels were also variable, being very high (5.5 -
16.8 × normal) in patients 3, 6, 7, and 8; high (1.2 - 4.4
× normal) in patients 1, 2, 4 and 5; and normal in
patient 9.
Features common to all were floppiness in infancy,
delayed motor milestones or failure to achieve walking,
brain white matter attenuation on MRI or CT (not done
in 1 patient) and development of joint contractures/foot
deformities. Eye and cardiac abnormalities were not
observed. In patients 3 and 5 respiratory compromise
was present, and both died of respiratory failure at 7
and 16 years, respectively.
In 1997 Allamand et al. [12] reported on a brother and
sister from a consanguineous Saudi family with the same
LAMA2 mutation as found in our patients (but charac-
terized as 3973 +2 T > C according to the previous
LAMA2 nucleotide sequence numbering). Both were
mildly affected: the boy at 3.5 years had muscle hypotonia
and inadequate head control, but walked at 26 months;
his younger sister also had hypotonia from early infancy
and poor head control and achieved walking at 3 years 8
months. Both had slightly reduced laminin a2c h a i n
expression as investigated by 2 antibodies recognizing the
G domain, and highly reduced expression using an anti-
body recognizing the N terminal. These results demon-
strated for the first time that use of more than one
antibody can provide valuable indications as to what
domain(s) of the laminin a2 chain may be affected in
CMD patients. Thereafter, this procedure became the
standard method for staining muscle of patients with
CMD and has also been used for prenatal diagnosis.
By contrast, in our patient 3, analyzed with 3 different
antibodies, laminin a2 chain expression was markedly
reduced: clearly more so than the cases described in
Allamand et al. [12]. He was the most severely affected
of our cases.
It is noteworthy that our cases show a much wider
clinical spectrum than suggested by the siblings
d e s c r i b e db yA l l a m a n de ta l .[ 1 2 ] :f r o mt h ev e r ys e v e r e
patient 3 and his brother (patient 4 who never walked
or sat unaided), to patients 1, 2, 8 and 9 who were still
walking at latest examination.
We previously reported two siblings from a consan-
guineous family with partial laminin a2 chain deficiency
due to an in-frame deletion and exceptionally mild clini-
cal manifestations [15]. The proband was a 39 year-old
man whose symptoms (difficulty in running and jump-
ing), first appeared at age 15 years and worsened very
slowly. When examined, the proband’ss i s t e rw a sf o u n d
to have a similar though even milder clinical picture.
Siala et al. [16] reported that clinical severity differed
between two siblings with the same out-of-frame muta-
tion in the LAMA2 gene, which was unrelated to lami-
nin a2 chain expression (completely undetectable in
both cases). Such clinical variability implies the presence
of other genetic or epigenetic factors able to influence
disease phenotype (see Heydemann et al. [17]).
The data of the present study provide further evidence
that the clinical spectrum of MDC1A is more heteroge-
neous than previously thought; motor achievement and
disease progression are particularly variable, making it
difficult to formulate prognoses even in patients with an
identical LAMA2- associated haplotype. Modifier genes,
such as those coding for proteins that interact with
laminin a2, and/or epigenetic factors, for instance those
involved in regulatory signaling functions, are likely to
contribute to the observed phenotypic variability. A
drawback of the present study is that muscle biopsies
were stained for laminin a2 in only 2 cases and exten-
sive immunohistological characterization was only possi-
ble in one case.
We emphasize, finally, that the identical intragenic
polymorphisms and upstream microsatellite markers of
the LAMA2 gene in our patients, strongly suggest a
founder effect. The mutation probably originated in
Saudi Arabia since studies on severe childhood autoso-
mal recessive muscular dystrophy (SCARMD), the com-
mon form of muscular dystrophy in North Africa and
the Arabian Peninsula [18-21] indicate that affected
families from the same tribe migrated from central
S a u d iA r a b i at ot h eS u d a n-c r o s s i n gt h eR e dS e a-i n
the 12th and 13th centuries [22]. Furthermore, in Saudi
Arabia the mutation may not be rare since we have
recently learned (personal communication of Dr. Tho-
mas L. Winder to SAM) of 3 Saudi patients with this
mutation, 2 of whom are homozygous and one who is
heterozygous. A few more cases, all originating from the
Middle East, are reported in the Leiden database http://
www.dmd.nl/. The clinical implication is that a laminin
a2 chain deficiency in Middle Eastern or Sudanese
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+ 2 T > C mutation in the LAMA2 gene.
Conclusions
Our data provide further evidence that the clinical spec-
trum of MDC1A due to a single mutation is heteroge-
neous, particularly in terms of motor achievement and
disease progression, making it difficult to give a reliable
prognosis even in patients with identical LAMA2-asso-
ciated haplotype.
The c.3924 + 2 T > C mutation to date has been
found only in patients originating from the Middle East
or Sudan; therefore laminin 2 chain deficiency in
patients from those regions should initially prompt a
search for this mutation.
Additional material
Additional file 1: Table S1. Clinical findings.
Additional file 2: Figure S1. Sequencing of genomic DNA from control
(A) and patient (B) showing the T > C transition at position +2 of the
consensus donor splice site of exon 26. Direct sequencing of the cDNA
revealing a 189 bp in-frame deletion, corresponding to aberrant skipping
of the whole of exon 26: (C) control and (D) patient.
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